| 2.17 -0.01 (-0.46%) | 09-19 15:20 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Vapotherm, Inc. is a medical technology company focused on creating and selling its unique high-velocity therapy products. These devices are designed to assist patients of all ages who are experiencing respiratory distress, with sales reaching both domestic and international markets. The company's primary offerings include its "Precision Flow" system lineup, featuring models such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox. These innovative systems deliver heated, humidified, and oxygen-enriched air at a high flow rate directly to patients through small-bore nasal interfaces. Beyond its core systems, Vapotherm also supplies a variety of essential accessories. The Vapotherm Transfer Unit enables patients to be moved between hospital areas or walk around while continuing their therapy. A Q50 compressor is available to provide the necessary compressed air for the Precision Flow systems. For medication delivery, the company offers an aerosol aeroneb adaptor, facilitating the provision of ultrasonic aerosolized medication, as well as an aerosol disposable patient circuit designed to streamline both continuous and intermittent aerosol drug administration. Tracheostomy adaptors are also part of their product range. Furthermore, Vapotherm manufactures ProSoft cannulas, engineered for comfortable skin contact, alongside various disposable items, including single-use components and nasal interfaces. Clinicians can also utilize Oxygen Assist Modules, which aid in keeping patient oxygen levels within a desired therapeutic range. The company distributes its medical products predominantly to hospitals. Vapotherm, Inc. was founded in 1993 and is based in Exeter, New Hampshire.
Mon, 23 Sep 2024
Latham & Watkins Advises SLR Capital on Completed Vapotherm Merger and Take-Private - Latham & Watkins LLP
Fri, 20 Sep 2024
Vapotherm Announces Closing of Merger - PR Newswire
Mon, 17 Jun 2024
Latham Advises SLR Capital on the Vapotherm Merger Take-Private - Latham & Watkins LLP
Mon, 17 Jun 2024
Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private - PR Newswire
Thu, 13 Oct 2022
New York Stock Exchange issues delisting warning to Vapotherm - nhbr.com
Sat, 10 Sep 2022
Vapotherm [NYSE: VAPO] | Top Respiratory Devices Solution Company 202 - MedTech Outlook
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|